Those aspiring to outpace the market meticulously engage in the process of selecting individual stocks. Strategic choices can be instrumental in accelerating your wealth.
In the latest session, VYNE Therapeutics Inc (NASDAQ: VYNE) closed at $0.43 up 5.91% from its previous closing price of $0.41. In other words, the price has increased by $5.91 from its previous closing price. On the day, 9.46 million shares were traded. VYNE stock price reached its highest trading level at $0.4565 during the session, while it also had its lowest trading level at $0.401.
Ratios:
For a deeper understanding of VYNE Therapeutics Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 7.60 and its Current Ratio is at 7.60. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
On November 18, 2024, BTIG Research started tracking the stock assigning a Buy rating and target price of $8.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Jan 15 ’25 when LEPORE PATRICK G bought 15,000 shares for $2.92 per share. The transaction valued at 43,800 led to the insider holds 51,472 shares of the business.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, VYNE now has a Market Capitalization of 10953031 and an Enterprise Value of -28668970. For the stock, the TTM Price-to-Sale (P/S) ratio is 22.82 while its Price-to-Book (P/B) ratio in mrq is 0.22. Its current Enterprise Value per Revenue stands at -60.229.
Stock Price History:
The Beta on a monthly basis for VYNE is 1.92, which has changed by -0.7663044 over the last 52 weeks, in comparison to a change of 0.16845357 over the same period for the S&P500. Over the past 52 weeks, VYNE has reached a high of $4.30, while it has fallen to a 52-week low of $0.28. The 50-Day Moving Average of the stock is 28.21%, while the 200-Day Moving Average is calculated to be -70.92%.
Shares Statistics:
For the past three months, VYNE has traded an average of 2.59M shares per day and 4118430 over the past ten days. A total of 25.47M shares are outstanding, with a floating share count of 22.45M. Insiders hold about 11.86% of the company’s shares, while institutions hold 27.66% stake in the company. Shares short for VYNE as of 1757894400 were 1030655 with a Short Ratio of 0.40, compared to 1755216000 on 2115574. Therefore, it implies a Short% of Shares Outstanding of 1030655 and a Short% of Float of 4.0700004.
Earnings Estimates
The stock of VYNE Therapeutics Inc (VYNE) is currently drawing attention from 2.0 analysts actively involved in the ongoing evaluation and rating process.The consensus estimate for the next quarter is -$0.13, with high estimates of -$0.12 and low estimates of -$0.14.
Analysts are recommending an EPS of between -$0.89 and -$0.89 for the fiscal current year, implying an average EPS of -$0.89. EPS for the following year is -$1.1, with 1.0 analysts recommending between -$1.1 and -$1.1.
Revenue Estimates
A total of 1 analysts believe the company’s revenue will be $100k this quarter.It ranges from a high estimate of $100k to a low estimate of $100k. As of. The current estimate, VYNE Therapeutics Inc’s year-ago sales were $121kFor the next quarter, 1 analysts are estimating revenue of $100k. There is a high estimate of $100k for the next quarter, whereas the lowest estimate is $100k.
